NCT02257489View on ClinicalTrials.gov

Phase 1 Study of ACE-083 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions
Musculoskeletal Diseases
Interventions
DRUG

ACE-083

recombinant fusion protein

Trial Locations (1)

68502

Acceleron Investigative Site, Lincoln

All Listed Sponsors
lead

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

INDUSTRY

NCT02257489 - Phase 1 Study of ACE-083 in Healthy Subjects | Biotech Hunter | Biotech Hunter